Skip to main content
OpenTrials
Completed

NCT Number: NCT01928823

Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia

Since decades, D-Cycloserine (DCS, drug class: Oxazolidinone) is proven to be an effective antibiotic agent in the treatment of tuberculosis. Furthermore it takes action in the central nervous system as an partial agonist on NMDA receptors. Because of glutamate mediated neuronal long-term potentiation in long-term memory DCS has an augmenting effect on emotional learning, as it occurs in exposure therapy of anxiety disorders. In this context we use DCS in addition to exposure therapy as a part of cognitive behavioral therapy (CBT) in patients suffering from agoraphobia with or without panic disorder. Thereby DCS is applicated oral as a capsule of 50mg, on three consecutive therapy sessions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Agoraphobia Anxiety Disorders Mental Disorders Panic Disorder Phobic Disorders

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin

Berlin, State of Berlin, 10117, Germany

About this study

The present study is a multicenter study with two participating institutions: The "Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin" and the "ZPHU - Zentrum für Psychotherapie am Institut für Psychologie, Humboldt-Universität zu Berlin". It is a randomized, placebo-controlled and double blind study with agoraphobic patients receiving a manualized cognitive behavioral therapy. The randomization and blindness refers to medication with an antibiotic called D-Cycloserine: One group receives D-Cycloserine after exposure sessions and the other group is treated with a placebo. The aim is to find out, whether or not D-Cycloserine augments psychotherapy outcome when administered after an exposure. Altogether, 78 patients will be treated. Before therapy, all patients receive a clinical examination to ensure that no contraindications for participating (like cardiac defects or serious central nervous system diseases) are present. In the following diagnostic sessions therapists conduct standardized assessments and after four diagnostic sessions therapy starts. All patients receive six therapy sessions, whereof three consist of exposures. When exposures are successful, D-Cycloserine or Placebo is administered afterwards. At the last therapy session another clinical examination to control several parameters is conducted. One month after therapy, two follow-up sessions with assessments take place.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • written consent (as per AMG §40 (1) 3b)
  • diagnosis of agoraphobia; severity of the disorder due to the CGI should at least be "moderately ill"
  • age: 18-75 years
  • negative pregnancy test for premenopausal women and safe contraception (Pearlindex < 1) during the study
  • accessibility (geographical vicinity) for treatment and follow-up
  • Compliance of the patient

Exclusion criteria

  • Known overreaction after taking of D-Cycloserine
  • Actual pharmacotherapy with ethionamides and/ or isoniazide
  • Judicial or regulatory hospitalization in a mental institution (as per AMG §40 (1) 4)
  • Severe psychiatric disorder like schizophrenia, addiction or dementia
  • acute suicidal tendency
  • epilepsy or other diseases concerning the CNS (e.g. brain tumor, encephalitis)
  • internal disease like severe hypertension, cardiac insufficiency, cardiac arrhythmia, severe dysfunction of liver or kidney, insulin-dependent diabetes mellitus or disorders of the hematopoiesis
  • lactation
  • changes in a psychopharmacotherapy or discontinuation of a pretreatment with psychoactive drugs less than 4 weeks previous to the begin of the study
  • disturbance of the day and night rhythm
  • disorder-specific psychotherapy
  • participation in another AMG-study during the last month previous to the inclusion in the study or during the participation in this study

Treatment and study plan

CBT

Behavioral

12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure

D-cycloserine

Drug

Administered for three times (50mg, oral) directly after exposure

Other names: "Seromycin" by Eli Lilly and Company

Primary outcomes

  1. Panic- and Agoraphobia Rating Scale (PAS)

    Time frame: Change from Baseline to Posttreatment (5 weeks)

    The PAS is designed for patients with agoraphobia or panic disorder who are at least 15 years old. It can be used to determine the severity of the disorder or to examine therapeutic success. There is a self-rating and a clinician-rating version available with 14 items each, yet the items are the same in both versions. Answers are given on a five-point Likert scale from "0" to "4" with higher scores indicating a higher severity. For determination of the severity of the disorder, 13 items are summed up, only item "U" (asking if panic attacks occur expected or unexpected) is not considered, resulting in scores between 0 and 52. There are also five sub scores if only special contents are of interest: Panic attacks, agoraphobic avoidance, anticipatory anxiety, disability, and worries about health.

    For the present study the German version of the questionnaire is used.

Secondary outcomes

  1. Beck Anxiety Inventory (BAI)

    Time frame: Change from Baseline to Posttreatment (5 weeks) and follow-up (9 weeks)

  2. Clinical Global Index (CGI)

    Time frame: Change from Baseline to Posttreatment (5 weeks) and follow-up (9 weeks)

  3. Agoraphobic Cognitions, Body Sensations Questionnaire and Mobility Inventory (AKV)

    Time frame: Change from Baseline to Posttreatment (5 weeks) and follow-up (9 weeks)

  4. Anxiety Sensitivity Index (ASI)

    Time frame: Change from Baseline to Posttreatment (5 weeks) and follow-up (9 weeks)

  5. Beck Depression Inventory first revised(BDI II)

    Time frame: Change from Baseline to Posttreatment (5 weeks) and follow-up (9 weeks)

  6. Brief Symptom Inventory (BSI)

    Time frame: Change from Baseline to Posttreatment (5 weeks) and follow-up (9 weeks)

Other outcomes

  1. Heart Rate Variability

    Time frame: Change from Baseline to follow-up (9 weeks)

    Furthermore HRV during the three exposure sessions will be investigated.

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Collaborators

  • German Federal Ministry of Education and Research

Registry information

Official study title

Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder

Acronym: Exposure-DCS

Important dates

Study start
2011
Primary completion
2014
Study completion
2014
First posted
Aug 27, 2013
Registry last updated
May 19, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.